Previous 10 | Next 10 |
BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter, ended September 30, 2022. The webcast and conference call wi...
Summary As Myovant overcame the odds as I forecast, Myfembree garnered another FDA approval to treat endometriosis. Subsequent to the said game-changing event, Sumitomo made an offer to acquire all outstanding shares at $22.75. However, Myovant's Board rejected the offer. It's...
Summary Myovant stock has rocketed in value by >100% since my last (bearish) note on the company. The main reason for the Myovant gains is an attempt by majority shareholder Sumitomo to acquire remaining shares for $22.75 per share. It's hard to understand why Sumitomo woul...
Myovant Sciences ( NYSE: MYOV ) hit a 52-week high of of $25.52 on Tuesday as the biotech continues to benefit after rejecting a $2.4B buyout offer on Sunday. So far today, shares are up ~4% . This comes after Monday's massive 36% gain . Analysts say that M...
Following a string of losses over the last couple of weeks, stocks bounced back on Monday. The Dow surged more than 700 points, while the S&P 500 rose about 2.6% -- just its second higher finish in the last 10 sessions. Among the leaders of the rally, energy stocks surged. A jump in...
Shares of Myovant Sciences (NYSE: MYOV) were skyrocketing 37.9% as of 11:32 a.m. ET on Monday. The huge gain came after the company announced that its board of directors' special committee rejected a proposal from Japanese drugmaker Sumitomo Pharma and its wholly owned subsidiary Su...
Myovant Sciences Ltd ( NYSE: MYOV ) opened nearly 35% up on Monday after the biopharmaceutical company said it rejected a buyout proposal from its largest shareholder. Myovant is open to considering a better offer Sumitovant Biopharma Ltd had sought to takeover the London-headqu...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Roman Tiraspolsky / Shutterstock.com Blue Apron (NYSE: APRN ) stock is sliding lower on Monday as investors react to its CFO leaving the company and plans for a stock sale. Starting with that CFO news,...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Myovant Sciences (NYSE: MYOV ) stock is skyrocketing over 30% today on news that the British biopharmaceutical company has received a buyout offer. MYOV stock surged as much as 31% in premarket trading after confirm...
Myovant Sciences ( NYSE: MYOV ) jumped 32% and traded above Sumitovant Biopharma's $22.75/share offer as analysts see the potential for an increased bid and possible interest from partner Pfizer ( PFE ). "In our view, we think Sumitovant’s offer appears s...
News, Short Squeeze, Breakout and More Instantly...
Myovant Sciences Ltd. Company Name:
MYOV Stock Symbol:
NYSE Market:
NEW YORK, NY / ACCESSWIRE / October 19, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myovant Sciences, Ltd. ("Myovant" or "the Company") (NYSE:MYOV). Investors who purchased Myovant securities are encouraged to obtain additional infor...
Third fiscal quarter 2022 total revenue of $100.2 million ; including net product revenue of $61.4 million Net product revenue from U.S. sales of ORGOVYX ® of $48.7 million in third fiscal quarter 2022, with sequential quarterly demand volume ...
MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences PR Newswire ...